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Objectives: This investigation examined human papillomavirus (HPV) in pregnant women in order to
characterize viral prevalence, types and concordance between infection in the cervix and in the oral cavity.
Methods: A total of 577 pregnant women seeking routine obstetric care were evaluated for HPV infection in
their cervix during gestation and immediately before delivery, and in the oral cavity during gestation. Male
partners present during the gestational clinic visit also provided a specimen from their oral cavity. HPV
assessment was performed by PCR, dot blot hybridization and DNA sequencing. A sexual and health
questionnaire was completed by the pregnant women.
Results: HPV prevalence in women was 29% in the cervix and 2.4% in the oral cavity. Among those with both
gestational and delivery specimens, 35% were infected at least once and 20% had infection at both intervals. At
delivery, 68% of infected women had an oncogenic HPV type in the cervix. There was no type-speciﬁc HPV
concordance between the two cervical specimens, nor cervical and oral results in women, nor with cervical and
oral ﬁndings between partners.
Conclusion: The lack of association in HPV positivity and types between the cervix and oral cavity in these
women suggests that self-inoculation is uncommon. This source of infection does not appear to be from oral
contact with a current male partner, since there also was no concordance between partners. These results
suggest either other modes of HPV transmission or differences in susceptibility to HPV infection or its clearance
in the oral cavity and genital mucosa.
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Human papillomavirus (HPV) in the genital area
is thought to be transmitted primarily through
direct mucosal contact and is causal in the
development of cervical cancer, in a larger
proportion of other carcinomas in the lower
genital tract, and in benign lesions
1. Persistent
infection with oncogenic, high-risk (HR) HPV
types is particularly associated with development
of these preneoplastic and malignant lesions
2,3 and
evidence suggests that progression of cervical
lesions is almost always associated with persistence
of HPV-HR types
2.
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cally during parturition
4–6. This proposition is of
concern since the prevalence of detectable
maternal HPV infection during pregnancy re-
portedly may rise during the second and third
trimester above that of non-pregnant women,
thus increasing the probability of HPV exposure
to perinatal transmission at the time of delivery
5,7.
There is evidence that the same viral types found
in cervical carcinoma are detected in and risks for
20–25% of head and neck cancers as well
8,9.
These include oncogenic mucosal types HPV-16,
18, 31, and 33
8,9. This consistency in viral types
in the different mucosal areas would further
suggest sexual transmission of HPV. Kellokoski
et al.
10, in one of the few published studies to
evaluate whether HPV types were similar in the
oral and genital sites of women, found only 3%
had HPV in their oral cavity. Concordance was
less than 1% despite the fact that the population
had a history of HPV genital lesions. To date, it is
still not clear whether pregnancy is associated
with an increased prevalence of HPV detected
during gestation, nor whether the prevalence and
types of HPV are the same in the oral cavity as in
the cervix generally.
The purpose of this study was to describe the
prevalence and types of HPV in the cervix and
the in oral cavity of pregnancy women and to
evaluate concordance between these two sites.
The ﬁndings will clarify our knowledge about
infection rates in pregnant women compared with
what is known about young non-pregnant
women. In addition, this will be one of the ﬁrst
large studies of prevalence and concordance rates
between genital and oral sites, and of possible
transmission routes between sexual partners.
METHODS
Study population
A total of 582 pregnant women who were being
seen for their routine obstetric examinations were
successfully recruited into the study between
September 1997 and November 2000 at the
Department of Obstetrics and Gynecology of the
University of Iowa medical college. Participants
gave informed consent to an approved university
human subjects consent form. The number of
women who refused was 83; 16 were too ill or
had complicated pregnancies; 11 had a language
barrier; 2 were mentally unable to consent to
participate; and 13 were not going to deliver at
the research hospital site and thus would not be
available for a cervical assessment of HPV at the
time of delivery.
Data collection
Questions about sociodemographics, tobacco and
alcohol usage, contraceptive practices, reproduc-
tive and sexual history and other risks of genital
intra-epithelial neoplasia (SIL), cancer, and con-
dylomata acuminata were asked at enrollment.
Patients were asked about previous history of
HPV-related genital diseases: cervical, vulvar, or
vaginal SIL or cancer, and genital warts. A
medical form was completed using the patient’s
medical chart, laboratory tests and physician
clinical evaluations, and included current and
historical data regarding abnormal Pap smear
diagnoses and previous history of HPV-related
genital conditions and treatments.
Pap smear and HPV specimen collection
Pap smears were collected to screen for current
cervical cytologic abnormalities and were fol-
lowed by a genital specimen to detect HPV
DNA. A pap smear was performed ﬁrst and results
were based on the Bethesda system
11. The
cervical HPV DNA specimen was collected with
an 20 cm cotton tipped swab dipped in 5 ml
normal saline and inserted in the vagina. The
cervix, the ectocervix and pooled secretions in
the posterior vaginal fornix were swabbed using a
circular motion to loosen squamous cells. The
swab was placed back into the tube of normal
saline and agitated in a circular motion to loosen
squamous cells, and was discarded before the tube
was capped. The second HPV DNA maternal
specimen was collected immediately before
delivery, regardless of whether the woman had a
vaginal or cesarean delivery. Specimens were
immediately refrigerated. A cell count was
performed using a hemocytometer and recorded
for use in the laboratory procedures to assure an
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the PCR reaction. Specimens were subsequently
frozen at 7808C until viral testing. The two
maternal cervical samples were collected by the
attending physician at 35 weeks’ gestation, on
average, and again during labor immediately
before delivery (at about 39 weeks).
Women with HPV infection detected at both
time periods were described as having persistent
infection, whereas those with HPV detected at
only one of the two time periods were said to
have non-persistent infection. The oral rinse
specimens were collected during the third
trimester clinic visit or, if women attended the
clinic only when in labor, it was collected at that
time. A total of 69 male partners who accom-
panied women at either of these times were asked
to participate and to submit an oral specimen for
HPV testing so that viral concordance could be
examined. Patients were asked to rinse the mouth
vigorously with 5 ml normal saline for 30 s and
expectorate into a pill cup which was then placed
in to a 10 ml tube and refrigerated. A cell count
and freezing were performed as described for the
cervical specimens. Because of inadequate oral
cell count 1 man and 2 women were excluded,
and another 3 women were excluded because the
oral specimen was collected some time after
delivery, leaving 577 women and 68 current male
partners in the study.
HPV DNA assessment
Procedures for sample preparation, PCR analyses
and DNA hybridization were described pre-
viously
12. In the DNA processing of the
specimens, repeat HPV-negative oral cells were
included as a control for contamination. All
processing of samples was performed in a building
separate from and before going to the research
laboratory for the day. The DNA extraction was
followed by the PCR reaction which included
positive controls containing 0.1 pg and 1.0 pg of
HPV plasmid DNA with the primers. Negative
controls were 0.025 mg of human DNA from oral
exfoliated squamous cells, normal saline and PCR
buffer. Ampliﬁcation with primers speciﬁc for b-
globin was used to conﬁrm the presence of
adequate cellular DNA in each specimen for HPV
DNA testing
13. Specimens repeatedly negative for
the b-globin fragment were excluded from the
analyses. No maternal or paternal specimens were
judged inadequate on the basis of the b-globin
result.
The primers used to identify HPV in the
samples, MY09 and MY11
14, are a mix of primers
amplifying a portion of the L1 gene of HPV types.
A primer to improve ampliﬁcation of HPV-51
also was included
3. Initially, ampliﬁed samples
were electrophoresed through agarose gels with
10
73 ml of the ampliﬁcation products to detect
HPV DNA. If specimens were band-negative,
they were hybridized by dot blot with the
inclusion of the GP5+ primer in a hemi-nested
fashion to determine which samples would require
re-ampliﬁcation for DNA sequencing
15. Each
sample prepared for initial PCR ampliﬁcation
contained 30000 nucleated cells. The dot blot
detected less than 10 SiHa cells in a spiked sample,
or less than 1 copy of HPV/1000 squamous cells in
sample specimens. When discordant HPV types
were found in separate samples from the pregnant
women, we performed additional PCRs with
type-speciﬁc primers which amplify portions of
the E6 ORF. This allowed additional HPV types
to be detected speciﬁcally in the presence of one
or more other types. E6 type-speciﬁc primers pairs
used in this study were: CAGGACCCACAG-
GAGCGACC and ATCGACCGGTCCACCG
ACCC amplifying nt 110-509 of HPV-16,
TGCCAGACCTGTGCACAACG and GCACC
GTCGACACTGTCCTG amplifying nt 147-510
of HPV-39, GGGAAACACCACGAACGCTG
and GCGCATTGCCCCGTCCAACG amplify-
ing nt 113-506 of HPV-51, and GCAAGGACTA
CGAGGTGGAC and TATGCCTGTACCTGA
TGCTC amplifying nt 139-457 of HPV-61.
HPV types were determined using DNA
sequencing of ampliﬁed HPV DNA evaluated at
the DNA Core at the College of Medicine
facilities. This was performed by dye-termination
on a DNA sequencer (Applied Biosystems-PE
Biosystems Group, Foster City, CA) and nucleo-
tide sequences were compared with GenBank
NCBI, NIH sequences using the BLAST pro-
gram
16. HPV types were deﬁned as either high-
risk (HR) or low-risk (LR) on the basis of types
that have been associated with cervical SIL,
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warts. Speciﬁc HPV types were identiﬁed if
there was a known type that matched by
490%. The HPV-HR types detected in this
study were: 16,18,31,33,35,39,51,54,58,59,68
and 70. HPV-LR types identiﬁed included:
6,11,38,44,53,56,61,66,69,83 and ﬁve unnamed
types (AF091451, AJ010822, L38388, U12480,
U12489, U12490). The unnamed types were all
related to benign and low-risk cutaneous HPV
types when a sequence comparison with Gen-
Bank was performed. Other samples were deﬁned
as ‘‘positive unclassiﬁed’’ when they were identi-
ﬁed as HPV based on the size of the band by
Southern blot but had insufﬁcient DNA for
typing. There were no cervical and only 0.3%
of oral samples in this category.
Data analysis
Logistic regression was used to examine the
association between HPV detection and potential
riskfactorsandtoexaminetheassociationbetween
ever HPV-related disease history or ever abnormal
Pap smear and persistent HPV groupings while
adjusting for other risk factors. HPV detection
outcomes included ever HPV positivity, persistent
HPV positivity, and persistent HPV-HR in cervix
samples and HPV positivity in oral rinse samples.
Adjusted odds ratios (ORs) were based on multi-
ple logistic regression models determined by a
backward stepwise selection procedure with sig-
niﬁcance set to p50.05. Variables considered in
the modeling process were: age, education, age at
ﬁrst intercourse, number of partners, number of
pregnancies and tobacco status. Ever HPV-related
disease history and ever abnormal Pap smear result
were included in the modeling process for HPV
detection only. Conﬁdence intervals (95% CI) for
ORs were calculated using the standard errors
from the corresponding logistic regression models
and the normal approximation. Due to low
positivity rates, exact logistic regression was used
to examine the association between HPV detected
in oral samples and potential risk factors at that site.
Pearson’s correlation coefﬁcient was used to
examine the association between two quantitative
variables. To determine if there was a signiﬁcant
difference in the HPV rates between the two
cervical specimen collections (gestation and deliv-
ery), McNemar’s test was used. All analyses were
performed using the SAS statistical package
17.
RESULTS
Table 1 shows the demographic characteristics and
potential risk factors of HPV in the cervix of 577
pregnant women comparing the 165 ever HPV-
infected women to the 412 HPV-negative deﬁned
as negative in the cervix at the time interval tested,
during pregnancy (C1) or labor (C2). The table
also includes separate analyses for the 60 women
with persistent HPV infection, deﬁned as HPV+
in both C1 and C2 specimens, compared with the
199 women who were HPV-negative at both of
these intervals. Controlling for age, number of
partners, smoking status, and history of HPV
disease, the overall risk of HPV detection was
greater in the youngest, unmarried, less educated,
those with 53 sex partners, and current cigarette
users. There was no signiﬁcant association with
parity or duration of oral contraceptive use (data
not shown). Those with a history of cervical SIL
and cancer had an elevated risk in the ever HPV+
group, whereas those with a current diagnosis of
ASCUS or L-SIL did not.
Those with persistent HPV infection had a risk
history similar to the HPV+ women overall
(Table 1), as did women with HPV-HR persistent
infection (data not shown). There were, however,
notable differences in the lack of association with
age and smoking but a much higher risk with 53
sex partners in the persistently infected. The 46
women with HPV detected in their cervix at only
one of the two time periods, a non-persistently
infected group, had risks similar to those for the
HPV+ women overall (data not shown). The
adjusted age-related risk was between that of the
ever HPV+ and the persistently HPV+ risk
(424 vs 533 years; adj.OR=2.6, 1.1–6.5).
Genital HPV prevalence and types
The cumulative HPV prevalence was 29% in the
cervix (Table 2). The most frequently reported
HR types were HPV-16, HPV-31, HPV-18, and
HPV-51; and the most common LR types
included HPV-53 and HPV-83. Among the 450
HPV prevalence in oral and genital mucosa E.M. Smith et al.
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26%, and among the 432 women with a C2
specimen the rate was similar at 25%. Based on
either time period, the ever HPV-HR rate was
18% and the ever HPV-LR was 13%. The
prevalence of HPV decreased markedly with
age: at 525 years it was 47%, at 25–30 years it
was 25% and at 430 years it was 20%. Those
525 years old were at signiﬁcantly greater risk of
infection than those 525 years old: OR=2.3,
1.4–3.6
HPV persistence and concordance
Among the 305 women with both C1 and C2
specimens, 35% were ever detected with HPV at
Table 1 Baseline demographic characteristics and risk factors for HPV in the cervix of pregnant women (n=577)
All HPV+ and HPV- women (n=577) Persistent HPV+ and HPV- women (n=259)
Characteristic n %HPV Adj. OR
4 95% CI n %HPV Adj. OR
5 95% CI
Age
3
424 140 47.1 4.0 2.4–6.7 58 37.9 1.7 0.7–4.4
25–29 223 25.1 1.6 1.0–2.6 111 18.9 1.3 0.6–2.9
530 214 20.1 1.0 – 90 18.9 1.0 –
Marital status
married 443 21.9 1.0 – 186 14.0 1.0 –
never married/div/sep 134 50.8 1.8 1.1–3.0 73 46.6 2.4 1.1–5.0
Education
3
412 132 47.0 2.0 1.0–3.8 68 44.1 7.0 2.7–18.0
13–16 254 28.7 1.5 0.9–2.6 112 19.6 1.9 0.7–4.7
517 191 15.7 1.0 – 79 10.1 1.0 –
Age ﬁrst intercourse
3
417 305 36.7 0.9 0.4–1.7 137 31.4 1.5 0.4–6.3
18–19 136 25.7 0.9 0.5–1.9 65 21.5 1.6 0.4–7.0
520 136 13.2 1.0 – 57 5.3 1.0 –
Number of partners
1–2 186 10.8 1.0 – 87 5.8 1.0 –
3–5 195 35.4 3.5 2.0–6.3 85 29.4 5.7 1.9–16.6
56 190 39.0 3.3 1.8–6.2 84 34.5 6.2 2.1–18.5
Parity
1 176 26.7 1.0 – 80 26.3 1.0 –
2–3 282 26.2 1.2 0.7–1.9 134 15.7 0.6 0.3–1.2
54 119 37.0 1.6 0.9–2.9 45 40.0 1.2 0.5–2.9
Smoking (pack-years)
Never 375 21.3 1.0 – 165 14.6 1.0 –
Past 122 33.6 1.1 0.6–1.8 56 32.1 1.7 0.7–4.4
Current 80 55.0 2.8 1.5–5.0 38 47.4 1.1 0.5–2.6
HPV-related disease history
Never 434 23.5 1.0 – 195 15.9 1.0 –
Condylomata 64 39.1 1.5 0.9–2.9 22 40.9 1.9 0.7–5.3
Cervical SIL 103 46.6 2.2 1.4–3.7 51 47.1 3.3 1.5–6.8
Cervical cancer 7 71.4 5.1 0.9–30.5 4 50.0 1.7 0.2–14.7
Pap smear
WNL 389 23.9 1.0 – 176 17.1 1.0 –
ASCUS 117 35.0 1.2 0.7–2.1 49 30.6 1.2 0.5–3.2
L-SIL 103 46.6 1.4 0.6–3.4 51 47.1 1.0 0.2–4.8
1Compared HPV+ vs. HPV-;
2HPV+ at C1 and C2 vs. HPV- at C1 and C2;
3in years;
4adjusted for age, number of partners, smoking status
and HPV-related disease history;
5adjusted for education, number of partners and HPV-related disease history, div, divorced; sep, separated
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signiﬁcant difference in the positivity rate be-
tween the gestational and delivery samples: 28% at
C1 and 26% at C2 (p=0.4). When examined for
prediction of HPV at the time of delivery based
on the result at C1, 56% (60/106) had persistent
infection. The most common persistent HR types
detected in the cervix were similar to those found
overall: HPV-16, HPV-31 and HPV-18. The
only LR type more frequently reported was
HPV-53. There was no difference in the
percentage between those who initially had a
negative HPV test at C1 and then were HPV+ at
C2 compared with the percentage whose gesta-
tional test was positive and then changed to
negative at delivery (9–11%).
Because ampliﬁcation with general primers
may fail to detect HPV types when dual infections
are present, type-speciﬁc PCR was performed
focusing on women with discordant HPV types.
In none of these cases was the discordance
resolved by detection of additional HPV types.
The type-speciﬁc concordance rate in the persis-
tently infected women was 67% 40/60), i.e. 47%
HR, 20% LR. Of those with HPV-HR types
detected during the C1 pregnancy sampling, 67%
(32) remained HR with the C2 delivery testing
and another 9% (22) who were HPV-LR or
negative at C1 subsequently converted to a HR
type at C2 (Table 3). At the time of delivery, 68%
of those with an HPV infection had a high-risk
type in the cervix.
HPV persistence, HPV-related diseases and
abnormal Pap smears
Women with a history of an HPV-related disease
had a higher frequency of infection. A previous
history was lowest in the HPV-negative, higher in
the non-persistent, and highest in the persistently
infected group (Table 4). When compared with
those who were HPV-negative for a history of an
HPV cervical lesion at both C1 and C2, the
adjusted ORs increased two to three times in
those with non-persistent or persistent infection.
The percentage having an abnormal Pap smear
during the study period also increased from lowest
in HPV-negative to highest in persistent infec-
tion, but only those with persistent infection had
a signiﬁcantly elevated risk with an abnormal Pap
smear. When only high-risk HPV types were
Table 2 HPV prevalence and types in the cervix and oral
cavity of pregnant women (n=577)
Cervix Oral cavity
HPV status n % n %
HPV+
1,2 165 28.6 14 2.4
HPV-HR
2 104 18.0 9 1.6
16 35 6.1 3 0.5
18 15 2.6 0 –
31 21 3.6 2 0.3
33 4 0.7 1 0.2
35 1 0.2 0 –
39 2 0.3 1 0.2
51 15 2.6 0 –
54 4 0.7 0 –
58 3 0.5 0 –
59 2 0.3 0 –
68 0 – 1 0.2
70 6 1.0 1 0.2
HPV-LR
2 73 12.7 5 0.9
6 7 1.2 1 0.2
11 3 0.5 0 –
38 1 0.2 0 –
44 1 0.2 0 –
53 11 1.9 0 –
56 2 0.3 0 –
61 10 1.7 0 –
66 5 0.9 0 –
69 1 0.2 0 –
83 11 1.9 0 –
+
5 0 – 2 0.3
AF091451 1 0.2 0 –
AJ010822 12 2.1 0 –
L38388 0 – 1 0.2
U12480 5 0.9 1 0.2
U12489 1 0.2 0 –
U12490 5 0.9 0 –
HPV persistence
3 60 19.7 – –
HR 32 10.5 – –
LR 16 5.2 – –
Concordance
4 40 13.1 – –
121 with different types during interval among those with both C1
and C2 samples, a single oral specimen collected;
2ever positive at
any time interval;
3among n=305 women with C1 and C2 sample;
4same type at C1 and C2: HPV-16 (11), HPV-18 (4), HPV-31 (5),
HPV-33 (1), HPV-39 (2), HPV-51 (2), HPV-54 (1), HPV-70 (2),
HPV-6 (1), HPV-11 (1), HPV-53 (2), HPV-61 (1), HPV-83 (1),
AJ010822 (2), U12480 (2), U12490 (2);
5HPV positive but could not
be classiﬁed by type
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infected groups had elevated adjusted risks.
Oral-HPV results
Among the 577 oral rinse specimens taken at the
time of the cervical HPV collection, only 2.4%
(14) of women were HPV+ in the oral mucosa
(Table 2). Almost all HPV types detected in the
oral cavity were detected in the cervix. However,
only 1% (6) had an infection in both the cervix
and the oral cavity at the same time, but none had
the same type detected in both mucosal areas. The
majority of oral infections were HR types and 2
were detected in women with a HR cervical
type: HPV-16 oral/HPV-58 cervix and HPV-68
oral/HPV-16 cervix. In contrast to genital HPV
infections, the frequency and risk of detection in
the oral cavity with HPV increased with age
(OR=1.1/year, 1.0–1.2) and parity 54
(OR=4.0, 1.2–13.7). Although not statistically
signiﬁcant, HPV-related risks associated with an
increased odds or oral infection included a history
of genital warts (OR=2.1) and cervical cancer
(OR=7.0). A prominent oral and cervical cancer
risk was elevated also in those infected in the oral
cavity: smoking duration 55 packyears
(OR=3.8, 1.1–12.8).
The HPV positivity rate in oral specimens
collected from 68 current male partners who
visited the clinic with the pregnant women was
5.9% (4). None of the infected men had female
partners who concurrently were infected in either
the oral or genital areas; thus there also was no
viral concordance between partners. Risk of
infection in the oral cavity of male partners was
associated with increasing number of female
partners: OR=1.1, 95% C.I=1.0–1.1, p=0.04
(data not shown). Of the positive oral specimens
in men, 1 was HPV-13, and 3 were high-risk
types: HPV-31 (2) and HPV-39 (1).
DISCUSSION
This is one of the ﬁrst studies of pregnant women
to examine concordance in HPV types from
multiple cervical specimens and between cervical
and oral sites from specimens which were
collected concurrently. The lack of concordance
in viral types in either of these mucosal sites in
pregnant women and between the detection in
cervical and oral contact between female and male
Table 3 HPV persistence and non-persistence in the cervix (n=305)
HPV type at delivery
HPV type at gestation High-risk Low-risk Negative Total
High-risk 32 (10.5%) 5 (1.6%) 11 (3.6%) 48 (15.7%)
Low-risk 7 (2.3%) 16 (5.3%) 15 (4.9%) 38 (12.5%)
Negative 15 (4.9%) 5 (1.6%) 199 (65.3%) 219 (71.8%)
Total 54 (17.7%) 26 (8.5%) 225 (73.7%) 305 (100.0%)
Table 4 HPV-related history, abnormal Pap smear and HPV infection
HPV-negative
1 (n=198) Non-persistent (n=46) Persistent (n=60)
Outcome % n % n OR 95% CI % n OR 95% CI
HPV-related disease history
2 17.2 34 34.8 16 2.1 0.98–4.4 48.3 29 2.9 1.5–5.6
Abnormal Pap smear
2 26.3 52 39.1 18 1.3 0.7–2.7 50.0 30 2.0 1.0–3.7
HR non-persistent (n=38) HR persistent (n=32)
HPV-related disease history
2 47.4 18 3.2 1.5–7.1 46.9 15 2.4 1.0–5.6
Abnormal Pap smear
2 55.3 21 2.7 1.3–5.6 50.0 16 1.8 0.8–4.1
1Missing Pap smear and HPV-related disease history for 1 woman;
2adjusted for number of partners
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auto-inoculation or by oral-genital sex between
partners is low. Alternatively, our ﬁndings may
indicate that clearance of HPV from one mucosal
site occurs independent of clearance from another
site or at different intervals. It remains to be
determined whether site-speciﬁc tropism of HPV
DNA strains can explain the presence of the virus
in one site but not another. Our ﬁndings do
support studies that suggest that the same HPV
types reported in the genitals are also found in the
oral mucosa.
Because of the timing and location of the
recruitment of pregnant women, we were unable
to collect specimens from current male partners
with which to determine genital HPV status and
types. Nonetheless, it is surprising that among the
infected males, none of their partners was infected
in either the oral or the cervical mucosa. The lack
of apparent concordance between partners in our
study does not preclude the possibility that males
were infected in their genitals and that this was
the reservoir of infection for HPV in their
partners. Although this source of HPV seems
the most plausible explanation for the lack of
concordance between partners, this premise is not
supported by available data. Koutsky and collea-
gues recently found that detection of oral HPV
was rare in their young adult population and was
not associated with oral-penile contact between
partners
18. They did not report on type-speciﬁc
concordance. Kellokoski et al.
19 reported the
HPV status of 33 current male partners in a cohort
of young women. Although the source of HPV
infection in the female genitals was thought to be
the current partner, there was no concordance in
viral types between the oral and anogenital sites of
male partners and the oral and cervical specimens
in female partners. Hippelainen et al.
20 also found
that HPV detected in the genitals of couples was
seldom identical, with only 5.6% agreement in
type. These reports support a hypothesis that the
source of currently detected infection may be
from an earlier sexual exposure or may be due to
infection which has cleared in the other partner or
at the other mucosal site.
Another explanation for the lack of concor-
dance between the oral and genital sites within
the pregnant women may be due to non-
persistent or intermittent detection of HPV over
time, as studies have shown in the cervix
21–25.
HPV positivity in the cervix has been shown to
increase with multiple sampling over time
22,24
whereas this phenomenon has not been studied in
the oral cavity. Oral and genital specimens may
need to be collected at multiple intervals to detect
ﬂuctuating levels of infection in an individual,
although it is questionable whether repeat
measurements would reduce differences in pre-
valence rates in the two mucosal sites of
individuals.
It is unclear whether there are attributes of the
oral mucosa that may protect it from the same
detectable level or viral infectiosity as in the
female genital region. Hormones, such as long-
term oral contraceptive use
26,27, have been
associated with increased risk of viral detection
and cervical SIL, and cancer. Other research
supports a hormonal link between number of
pregnancies and current pregnancy status asso-
ciated with a higher prevalence of viral detection
and risk of genital cancer
7,28,29. However, neither
oral contraceptive use nor parity in this study
showed a clear pattern of risk for HPV detection.
Thus it is likely that the mechanism of risk or
detectability is associated with other factors. Oral
saliva has been shown to be protective against
infections through the existence of a number of
oral antimicrobial agents such as lysozyme,
lactoferrin, sIgA and cytokines
30–32. In addition,
the highly keratinaized tissue that characterizes
the oral cavity may provide a barrier against HPV
infection, making it less likely that the virus will
invade and reach the basal cell layer than in the
cervical mucosa.
Our investigation showed no signiﬁcant
change in the rate of genital HPV DNA
prevalence between the third trimester and
delivery. This outcome supports some ﬁnd-
ings
6,33,34 but is in contrast to investigations
which found either a rise between the ﬁrst and
second or third trimesters
6,7 or a drop in rate after
34 weeks at the time of delivery or postpartum
35.
The hypothesis of a higher rate during the later
trimesters is consistent with the increasing rise in
the progesterone level as pregnancy progresses.
Progesterone has been shown to enhance the
transcription and replication of genital HPV
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sponse element found in the long control region
of the viral genome
36,37. Because we did not
focus on women in their ﬁrst trimester of
pregnancy, we cannot establish whether their
prevalence rate increased between early gestation
and later in pregnancy when there were higher
levels of progesterone.
A drop in the detection of HPV at the time of
delivery is an issue of importance since it may
indicate the level of risk from vertical transmission
before a vaginal delivery, when the newborn is
considered at greatest risk of infection. Several
studies
38,39 including ours
33 have shown reduced
immune responses in pregnant women, suggest-
ing that hormonal effects allow increased
replication of infection. We found reduced
humoral response to HPV-16 among pregnant
compared with non-pregnant women, which
dropped progressively by trimester and increased
after delivery. A study of local anti-HPV
antibodies in cytologically normal women in-
dicated that during late pregnancy
39 partial
suppression of local immunity may have ac-
counted for the relatively poor antibody responses
compared to postpartum. That led to a signiﬁcant
rise in the anti-HPV IgA positivity against HPV
antigens E2, E7 and L1. De Rosa Husman et al.
40
found an age-related pattern which may explain
in part why study ﬁndings differ in regard to
positivity rate by trimester. Women aged 15–29
years had a higher prevalence of HPV regardless
of trimester compared with women over 30 years
of age, but only a slightly higher rate associated
with gestational age. Although we found an
increased risk of HPV detection in patients 424
years old who had second-trimester samples
compared with those 430 years old, the risk
was similar (OR=2.9, 0.7–13.1) when compar-
able age groups were evaluated in third-trimester
women (OR=3.4, 2.0–5.8).
One of the strengths of this study was the large
number of women from whom both genital and
oral specimens were obtained, so that concor-
dance between these two sites could be more
adequately addressed. Another advantage was our
specimen collection and laboratory procedures
which reduce the potential for false-negative
results. Great caution is taken to incorporate an
adequate and comparable number of nucleated
squamous cells in each PCR reaction regardless of
the original number of cells collected. Our
procedures signiﬁcantly reduced false-negative
detection due to insufﬁcient specimen collection.
Only 0.5% of women had to be eliminated from
the study because of an inadequate cell count.
This was the ﬁrst study to use sequencing to assess
genital and oral HPV concordance, which further
reduced the likelihood of false positive by
identifying the speciﬁc type and sequence match
to known HPV types. This also diminished the
reporting of unknown types which may either
not represent an HPV infection or may be due to
contamination effects. Further, discordance in
type within individuals was not resolved by
independent testing of samples with PCR
ampliﬁcation with type-speciﬁc primers directed
at the E6 open reading frame of HPVs. This
suggested that the lack of detection was not due
to an inability of general PCR to detect multiple
HPV types in these cases.
The apparent lack of association between HPV
types in the cervix and oral cavity of women and
between current partners in our study indicates
that a number of issues remain unclear about
transmission routes and infectivity of this virus.
Other published investigations evaluating infec-
tion at these two sites have shown little
concordance between sex partners as well
24,25.
Retrieving oral and genital specimens from both
partners concurrently is likely to be difﬁcult other
than in populations seeking treatment for an
abnormal Pap smear or a sexually transmitted
disease, as in the populations of both of these
previous oral-genital investigations. Such groups
are likely to be biased samples and may not reﬂect
the general population prevalence and concor-
dance rates. Most studies evaluating concordance
have focused exclusively on genital infection
between heterosexual partners who also had
either HPV infection or an HPV-related disease
rather than on healthy couples
41–45. The outcome
of these investigations is one of mixed results in
the degree of concordance between partners.
More information about the biological behavior
of the virus at different anatomical sites is needed
better to understand these ﬁndings and the
mechanisms of transmission.
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